17 results about "HSP60" patented technology

The invention discloses an application of an engineered exosome rich in SIRT3 in preparation of a medicine for improving mitochondrial dysfunction. The method comprises the following steps: screening to obtain a polypeptide molecular gel G12 targeting HSP60, forming a fusion protein SIRT3-G12 from the G12 and SIRT3, constructing a recombinant plasmid for expressing the fusion protein, transfecting cells, culturing, and extracting an exosome, thereby obtaining the engineering exosome SIRT3-Exo rich in SIRT3. The SIRT3-Exo is used for treating mitochondrial dysfunction, and the research shows that the SIRT3-Exo can remarkably promote mitochondrial oxidative phosphorylation, promote expression of cell antioxidant enzymes and deacetylation of FOXO3a, enhance the antioxidant capacity of cells and remove ROS in the cells, and has the effect of promoting mitochondrial function recovery. The problem that SIRT3 cannot be used for treating mitochondrial dysfunction through exosomes is solved, and good application prospects are achieved.

The application belongs to the technical field of biological medicine, and particularly relates to application of an inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein. The application provides application of the inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein in preparation of a medicine for preventing and / or treating psoriasis, and an amino acid sequence of the HSP60 protein (heat shock protein 60) is shown as SEQ ID NO. 1. The application provides a brand-new, mechanism-driven psoriasis treatment target, lactic acid modification of lysine at the 249th position of HSP60 protein. By inhibiting the specific modification, the purpose of precise intervention and treatment from an upstream of the disease is achieved by stabilizing mitochondrial function and blocking intrinsic immune activation triggered by metabolic stress.

Provided here are methods directed to the T cell receptor cloning of heat shock protein 60 (HSP60), the generation of HSP60-specific regulatory T cells (Tregs), and adoptive cell transfer of HSP60-specific Tregs for the treatment of autoimmune and other disorders. Methods of treatment also include administering a therapeutically effective amount of an inhibitor of expression or activity of nucleus accumbens-associated protein- 1 (NAC1) along with the HSP60-specific Tregs.

The present disclosure relates to HSP60 inhibitor compounds, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat cancer.

The invention belongs to the technical field of gene engineering, and provides Hsp60 receptor targeted recombinant lactobacillus plantarum as well as a construction method and application thereof, lactobacillus plantarum is taken as a host, pPG612 is taken as an expression vector, and CsgB gene or CsgF gene is expressed. The two engineering probiotics can express target protein and can be stably expressed on the surfaces of thalli, the AB.9 intestinal epithelial cells can be effectively adhered, and the adhesion and invasion of the A.veronii to the AB.9 cells can be inhibited. And secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the IgT secretion of intestinal mucus. The engineering bacteria can be competitively combined with an intestinal epithelial cell Hsp60 receptor, down-regulate p65 expression, inhibit NF-kappa B signal channel activation, regulate intestinal tight junction protein redistribution and down-regulate proinflammatory factor expression through a TLR4 / TLR5 dependent NF-kappa B signal channel, and the engineering bacteria can increase the abundance of effective microbial communities in the intestinal tract of the snakeheaded fish, so that the growth of the snakeheaded fish is promoted, and the growth of the snakeheaded fish is promoted. And the flora can transfer, mediate and activate immune response through a feeding environment.

The invention discloses an application of an SIRT3 enriched exosome in preparation of a medicine for improving myocardial ischemia reperfusion injury. The preparation method comprises the following steps: screening to obtain polypeptide molecular gel G12 targeting HSP60, forming recombinant protein SIRT3-G12 from the G12 and SIRT3, constructing recombinant plasmids for expressing the recombinant protein, transfecting cells for co-expression, and extracting exosomes, thereby obtaining the SIRT3-enriched exosome SIRT3-Exo. In a cell experiment, the SIRT3-Exo has the effects of improving the mitochondrial metabolism function and reducing the oxidative stress and apoptosis level of the cells on hypoxia reperfusion myocardial cells. In an animal experiment, SIRT3-Exo is injected into a myocardial ischemia area of an I / R rat, so that the cardiac function is remarkably improved, the oxidative stress and inflammatory injury level is reduced, and angiogenesis is promoted. The result shows that the SIRT3-Exo has an obvious improvement effect on the myocardial ischemia reperfusion injury.

The invention discloses a preparation method and application of a bivalent feline calicivirus VLP vaccine, an insect cell endogenous molecular chaperone protein HSP60 is creatively utilized to construct a recombinant plasmid co-expressing HSP60 and FCV VP1, and the expression quantity of VP1 is successfully improved, the expression quantity of GII VP1 is improved by 9.2 times, and the expression quantity of GI VP1 is improved by 17 times. By screening assembly buffer solutions with different salt ion concentrations, pH values and components, the assembly conditions of GI VLP and GII VLP are optimized, and the yield and yield of VLP are improved. Animal model evaluation shows that the bivalent VLP vaccine has an immune synergistic effect, the immune effect of the bivalent VLP vaccine is remarkably superior to that of a monovalent VLP vaccine and a commercially available inactivated vaccine, the same immune effect of a high dose can be achieved by a low dose of the bivalent VLP vaccine, the antigen dose demand is reduced by 4-8 times, meanwhile, protection on two FCV types is provided, and a new direction is provided for research and development of FCV vaccines.

The invention relates to the technical field of bioengineering, in particular to sphingomonas engineering bacteria for producing welan gum and a fermentation method. According to the engineering bacterium disclosed by the invention, the gene for coding Hsp60 is transferred, so that the robustness of the sphingomonas engineering bacterium is improved, renaturation and folding of protein in the bacterium are promoted, especially the normal function of the protein is maintained in a high-viscosity, high-permeability and low-oxygen adverse environment in the later stage of fermentation, the synthesis efficiency of a product is improved, the growth of the bacterium is promoted, and the yield of the bacterium is increased. Therefore, the yield and the quality of welan gum production are improved.

The invention relates to a mycobacterium abscessus and marine mycobacterium vaccine and a preparation method thereof, the mycobacterium abscessus and marine mycobacterium vaccine comprises a recombinant plasmid based on an antigen protein gene, the recombinant plasmid is used for stably expressing cell wall antigen protein, and the recombinant plasmid is used for stably expressing cell wall antigen protein. The recombinant plasmid sequentially contains a resistance screening gene Kan, an escherichia coli replicon oriE, a promoter hsp60, an antigen protein gene MMAR1296 and a gene tag Flag-tag in the clockwise direction, wherein the DNA (deoxyribonucleic acid) sequence of the promoter hsp60 is as shown in SEQ ID No.1; the recombinant plasmid sequentially contains a resistance screening gene Kan, an escherichia coli replicon oriE, a promoter hsp60, an antigen protein gene MMAR1296 and a gene tag Flag-tag in the clockwise direction; the sequence of the antigen protein gene MMAR1296 is as shown in SEQ ID No. 2; and the DNA (Deoxyribose Nucleic Acid) sequence of the gene tag Flag-tag is as shown in SEQ ID No. 3. According to the invention, cell wall antigen protein MMAR1296 from marine mycobacterium is displayed on the surface of a mycobacterium smegmatis Msmeg vaccine carrier without any toxicity, a recombinant strain and a vaccine thereof are constructed, and subcellular component separation and western-blot experiments prove that the antigen protein MMAR1296 is successfully displayed on the surface of mycobacterium smegmatis MC2155; balb / c mouse in-vivo experiments prove that the immune effect of the recombinant mycobacterium smegmatis vaccine with the MMAR1296 antigen protein displayed on the surface is far superior to that of a bacillus calmette guerin vaccine BCG.

The invention discloses an application of interaction of cFKBP8-Hsp60 in depression by adjusting mitochondria. Belongs to the technical field of molecular biology and medicine, the interaction between cFKBP8 and Hsp60 is ensured, the key amino acid residue of the interaction between cFKBP8 and Hsp60 is confirmed to be the 13th arginine (cFKBP8 ARG13) of cFKBP8, and the cFKBP8 is overexpressed in SH-SY5Y cells and mouse leading edge cortical neurons by further constructing an expression vector; the results show that the mitochondrial structure and function are damaged, and the mouse shows stress susceptibility, however, the mutation of cFKBP8 ARG13 into alanine alleviates mitochondrial damage and the stress susceptibility of the mouse. Therefore, based on a molecular mechanism of adjusting mitochondria by a cFKBP8-Hsp60 axis, a new thought and a treatment target are provided for the treatment of depression.

The invention discloses application of vanadium pentoxide nanoparticles NIP-FOS or NIP-PVP in preparation of drugs for treating pancreatic cancer, and belongs to the field of research and development of new drugs. According to the invention, a KC (LSL-KrasG12D, Pdx1-Cre) mouse primary pancreatic cancer model is adopted to prove that the vanadium pentoxide nanoparticles NIP-FOS and NIP-PVP have a good treatment effect on pancreatic precancerous lesions PanIN, and the vanadium pentoxide nanoparticles NIP-FOS and NIP-PVP are generated by targeting HSP60 and M2 macrophages. The invention provides a basis for taking the vanadium pentoxide nanoparticles NIP-FOS and NIP-PVP as a novel medicine for treating pancreatic cancer.

The application belongs to the technical field of genetic engineering, and provides Hsp60 receptor targeted recombinant plant lactobacillus, a construction method and application. The plant lactobacillus is used as a host, pPG612 is used as an expression vector, and CsgB genes or CsgF genes are expressed. Two strains of engineering probiotics can express target proteins and can stably express on the surface of the bacterial body, effectively adhere to AB.9 intestinal epithelial cells, and can inhibit the adhesion and invasion of AB.9 cells. A. veronii Secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the secretion of intestinal mucus IgT. The engineering bacteria can also competitively bind to the Hsp60 receptor of intestinal epithelial cells, down-regulate the expression of p65 through the TLR4 / TLR5 dependent NF-κB signal pathway, inhibit the activation of the NF-κB signal pathway, regulate the redistribution of intestinal tight junction proteins, and down-regulate the expression of pro-inflammatory factors. Furthermore, the engineering bacteria can increase the abundance of intestinal beneficial flora of the snakehead, and the flora can mediate and activate the immune response through the feeding environment.

The invention discloses a target protein-enriched exosome based on polypeptide molecular glue and a preparation method of the target protein-enriched exosome. The preparation method comprises the following steps: incubating and culturing a phage library and HSP60 recombinant protein to screen HSP60-targeted polypeptide molecular glue G12, constructing recombinant plasmids for expressing target protein-polypeptide molecular glue G12 fusion protein based on the polypeptide molecular glue G12, and transfecting cells for culture; the polypeptide molecule glue G12 is linked with HSP60 in the target protein targeted exosome to realize trans-organelle transport, so that the target protein is enriched into the exosome, and then the exosome rich in the target protein is obtained through extraction. The invention provides a theoretical basis for clinically delivering the target protein which does not exist in the exosome in a natural state so that the target protein can play a therapeutic role through the exosome.

To provide an oligonucleotide enabling accurate grasp of the initial onset of Welsh onion white rot and a method for detecting both group A and group B strains of Sclerotium cepivorum.SOLUTION: The detection method according to the present invention uses an oligonucleotide of 15-30 base-length that is capable of annealing to any one region, or a complementary region thereof, selected from gene regions of glyceraldehyde-3-phosphate dehydrogenase (G3PDH), heat shock protein 60 (HSP60), and calmodulin (CaM) of plant-pathogenic Ascomycota, the region being conserved in both group A and group B strains of Sclerotium cepivorum and exhibiting polymorphisms in Botrytis, Dumontinia, Macrophomina, Sclerotinia, and Sclerotium., Sclerotinia, and Sclerotium.SELECTED DRAWING: Figure 7

The invention discloses a carborane HSP60 / HIF-1 inhibitor and application, and belongs to the technical field of medicine preparation and new application. A series of novel carborane derivatives HPLC are designed and synthesized, and the series of compounds can efficiently inhibit the expression of HIF-1 by targeting HSP60, show good inhibitory activity on HIF-1HSP60, and inhibit malignant development processes such as tumor cell invasion, clone proliferation and the like. The inhibitor can be applied to preparation of drugs for inhibiting cancer development.

The present invention relates to a biomarker for predicting the prognosis of colorectal cancer by using changes in the expression level of HSPD1 gene mRNA or HSP60 protein encoded by these genes, and a method for predicting prognosis using the same. By analyzing the expression level of HSPD1 gene or HSP60 protein, the prognosis of colorectal cancer patients can be predicted in clinical practice, and by performing the analysis in combination with TNM classification, more advanced prediction is possible and personalized strategies can be designed.

The invention relates to the technical field of bioengineering, and discloses an application of a heat shock protein in preparation of a medicine for treating subarachnoid hemorrhage, and the heat shock protein is HSP60. Wherein the expression of HSP60 is up-regulated after subarachnoid hemorrhage of a mouse, and NLRP3 inflammasome assembly is promoted by activating a TLR4 / MyD88 / NF-kappa B signal channel in cells, so that pyroptosis of microglial cells is induced, and early brain injury is aggravated; the invention further provides a product for treating / inhibiting subarachnoid hemorrhage. The invention discloses a key effect of HSP60 on induction of pyroptosis of microglial cells through a TLR4 / MyD88 / NF-kappa B-NLRP3 signal axis in SAH-induced early brain injury for the first time, and proves that mizoribine can effectively relieve neuroinflammation and brain injury by inhibiting HSP60.